SCHEMBL333480

SCHEMBL333480

CCN(CC)c1ccc(-n2c(CC(=O)O)c(C(=O)O)c3cc(Oc4ccc(C(=O)O)cn4)ccc32)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
HRH3 Q9Y5N1 1/20 0.37
MAPT P10636 4/20 0.36
ALDH1A1 P00352 3/20 0.35
LMNA P02545 2/20 0.35
TSHR P16473 2/20 0.35
MAPK1 P28482 1/20 0.35
ATM Q13315 1/20 0.35
KDM4E B2RXH2 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
GRM2 Q14416 1/20 0.35
CYSLTR1 Q9Y271 1/20 0.35
OPRM1 P35372 2/20 0.34
OPRD1 P41143 2/20 0.34
HTT P42858 1/20 0.34
RARB P10826 1/20 0.34
RARG P13631 1/20 0.34
P2RX3 P56373 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL332540 0.82 USP14 (0.47) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL334181 0.80 PPARG (0.43) MEN1KMT2AKDM4EPPARG
SCHEMBL334064 0.80 USP14 (0.43) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL333566 0.80 PPARG (0.41) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL333954 0.80 MEN1 (0.40) MEN1KMT2AHRH3MAPTALDH1A1
SCHEMBL1407633 0.76 ACACB (0.38) MEN1KMT2AKDM4EP2RX3
SCHEMBL333427 0.75 SCN9A (0.42) MAPTLMNASMN1; SMN2NPSR1HTT
SCHEMBL333764 0.75 PPARG (0.42) LMNAPPARG
SCHEMBL333844 0.73 MEN1 (0.45) MEN1KMT2AMAPTTSHRSMN1; SMN2
SCHEMBL333628 0.72 MEN1 (0.42) MEN1KMT2AMAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097623-B2 1-Aryl-or heteroaryl-3-aryl-or heteroarylindole-2-carboxylic acids or esters: e.g., 5-(4-tert-Butylphenyl)-1,3-bis(4-isopropoxyphenyl)-indole-2-carboxylic acid; inhibition of the activity of microsomal prostaglandin E synthase-1, leukotriene C4 and/or 5-lipoxygenase-activating protein; analgesics BIOLIPOX AB (SE) 2012-01-17 US disclosed
EP-1841735-B1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2011-03-09 EP disclosed
US-20090076004-A1 Indoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2009-03-19 US disclosed
CN-101142185-A Indoles useful in the treatment of inflammation BIOLIPOX AB (SE) 2008-03-12 CN disclosed
EP-1841735-A1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION Biolipox AB (SE) 2007-10-10 EP disclosed
WO-2006077366-A1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2006-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076004-A1 Indoles Useful in the Treatment of Inflammation IDO1, IDO2, AREG MEN1 2066/4885KMT2A 3484/4885HRH3 207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.